Leading by example

Board of Directors

Chairman & Managing Director
Glenn Saldanha
+
Chairman & Managing DirectorGlenn Saldanha

Mr. Glenn Saldanha is the Chairman & Managing Director of Glenmark Pharmaceuticals Ltd. He joined in 1998 as Director and took over as Managing Director & CEO in 2001.

As Chairman & Managing Director of the Company, Mr. Saldanha oversees all operations of the organization. During his tenure, he transformed Glenmark into a truly global organization with revenue over a billion dollar and commercial presence in over 80 countries. Under his leadership, Glenmark has evolved from an Indian branded generics business, into a research-driven and innovation-led organization. Mr. Saldanha’s vision is to discover, develop and take to market India's first innovative drug for the entire world.

Mr. Saldanha holds a bachelor’s degree in pharmacy from Mumbai University and is an MBA from the Leonard Stern School of Business at New York University. Prior to Glenmark, he has worked with Eli Lily, USA and PriceWater House Coopers, USA.

Executive Director and Global Chief Financial Officer
V. S. Mani
+
Executive Director and Global Chief Financial OfficerV. S. Mani

Mr. V. S. Mani is an executive member of the Board of Directors and is also the Global Chief Financial Officer of Glenmark Pharmaceuticals Ltd. He is responsible for the company’s worldwide finance operations and secretarial function, including global accounting, financial reporting, tax and treasury. He has over 25 years of rich industry experience across treasury, taxation (direct, indirect & international), accounting, financial planning & analysis, secretarial, legal, audits (internal & statutory), risk management and investor relations.

Prior to joining Glenmark in 2017, he was the President Finance at the Bhartiya Group. He has also held the position of the Chief Financial Officer at Cipla and played a key role in acquisition of various companies in emerging and mature markets for the organization. He is a qualified Chartered Accountant.

Executive Director – Corporate Services
Cherylann Pinto
+
Executive Director – Corporate ServicesCherylann Pinto

Ms. Cherylann Pinto is an executive member of the Board of Directors and is one of the promoters of Glenmark Pharmaceuticals Ltd. She has over 30 years of pharma industry experience and has been associated with Glenmark since 1999. As Executive Director – Corporate Services, she heads Glenmark’s Human Resources, Corporate Communications, Corporate Social Responsibility, Information Technology, Administration and Insurance functions. Prior to her association with Glenmark, Ms. Pinto had founded a pharmaceutical company where she was the Managing Director for 10 years.

Glenmark’s CSR initiatives under her leadership have been recognized by the Bombay Chambers of Commerce Award 2014 for the contribution in the area of Child Health, reducing malnutrition & infant mortality, improving medicine access and providing sustainable livelihood. Ms. Pinto has received the ‘Women Leadership Award’ at the CMO Asia’s 5th Best CSR Practices Award in 2015 and was also acknowledged as one of the 100 Most Impactful CSR Leaders Globally by the World CSR Congress in 2017.

Ms. Pinto holds a Bachelor’s Degree in pharmacy from the Institute of Chemical Technology (ICT) in Mumbai and has also completed The General Management Program from the Harvard Business School in Boston.

Independent Director
Rajesh V Desai
+
Independent DirectorRajesh V Desai

Mr. Rajesh V. Desai is a Non-Executive Director at Glenmark Pharmaceuticals Limited. Mr. Desai has over 34 years of work experience. He was the Chief Financial Officer of Glenmark till 2016. He led the Finance, Legal & IT functions and with his strong Finance background, he contributed significantly to the growth story of Glenmark.

Mr. Desai holds a Bachelors Degree in Science (B.Sc.) from the Bombay University and is a Chartered Accountant from Institute of Chartered Accountants of India (ICAI).

Independent Director
Brian W Tempest
+
Independent DirectorBrian W Tempest

Dr. Brian W. Tempest is the Editor of the Journal of Generic Medicines. He is also a Non-Executive Director on the Governance Board of the United Nations Patent Pool. Previously he worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non-Executive Director until 2008.

Dr. Tempest has also worked for Glaxo as Regional Director Far East and Regional Director Middle East & Africa from 1985 to 1992. He has worked in the Pharmaceutical Industry for the last 45 years and has managed Healthcare businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India.

Dr. Tempest is now a Non-Executive Director of Petainer-Innopac. He is a member of the SCRIP Global awards panel. He is also an international advisor to UNCTAD and MAPE, an Indian M&A boutique. Dr. Tempest has a PhD in Polymer Chemistry from Lancaster University and a D.Sc. (Hon) from Aston University, UK. In 2009 he became Chairman of the Advisory Board for the Lancaster University Management School, UK. He is a Fellow of the Royal Society of Medicine, a Fellow of the Royal Society of Chemistry and is a Chartered Chemist.

Independent Director
Saira Ramasastry
+
Independent DirectorSaira Ramasastry

Ms. Saira Ramasastry has over 20 years of experience in life sciences industry successfully building companies as an advisor, board member and operational executive. She is the Founder & Managing Partner of Life Sciences Advisory, LLC and is also associated with the European Prevention of Alzheimer’s Dementia (EPAD) as head of Business & Sustainability where she is currently leading processes to create $50 million public private consortium focused on Alzheimer’s Dementia (AD) prevention. She is also a Strategic Advisor to G8 Health Initiatives and is the Co-Founder and President of the For Life Institute. She serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research and the Advisory Council for Judge School of Business at the University of Cambridge. She is also a Health Innovator Fellow of the Aspen Institute.

Ms. Ramasastry accomplishments include being named as top life sciences advisor by Acquisition International and CorporateLiveWire. Her past experiences include leading emerging biotechnology investment banking coverage for Merrill Lynch for over a decade and as a healthcare M&A analyst at Wasserstein Perella.  

Ms. Ramasastry is B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University where she graduated Phi Beta Kappa. She also holds M.Phil. in Management Studies from the University of Cambridge.

Independent Director
Bernard Munos
+
Independent DirectorBernard Munos

Mr.Bernard Munos is a Senior Fellow at FasterCures, a center of the Milken Institute. His research on pharmaceutical innovation has been published in Nature and Science, as well as profiled by Forbes magazine. The popular industry newsletter FiercePharma has named him one of the 25 most influential people in biopharma. 

Mr. Munos advises organizations on being better innovators. He serves on the Advisory Council of the National Center for Advancing Translational Sciences (NCATS); is a member of the National Academy of Medicine's Forum on Drug R&D and Translation; an Advisor to the journal Science Translational Medicine; and an Advisor to or Board member of multiple companies and publicly-financed research organizations.

Mr. Munos has discussed his research at numerous meetings sponsored by the President's Cancer Panel, the NIH Leadership Forum, the FDA, the World Health Organization, the OECD, the New York Academy of Sciences, the Brookings Institution, the Kauffman Foundation, the US Patent and Trademark Office, the American Chemical Society, as well as leading universities in the US, Europe, and Asia. He also blogs about innovation for Forbes and FastCures.

Mr. Munos received his MBA from Stanford University, and holds other graduate degrees from University of California at Davis, and the Paris Institute of Technology for Life, Food and Environmental Sciences in France. 

Non-Executive Director
Blanche E. Saldanha
+
Non-Executive DirectorBlanche E. Saldanha

Mrs. Blanche E. Saldanha is a Non-Executive Director and a member of the promoter group of Glenmark Pharmaceuticals Limited. Prior to this position, Mrs. Saldanha was the Director – Exports and managed Glenmark’s international operations from 1982 to 2005. During her 23 year tenure with the organization, she was responsible for developing and growing the company’s export business.

Mrs. Saldanha holds a Bachelors Degree in Science (B.Sc.) and a Bachelors Degree in Education (B.Ed.) from Bombay University.

Independent Director
Sridhar Gorthi
+
Independent DirectorSridhar Gorthi

Mr. Sridhar Gorthi is a partner in the Mumbai office of Trilegal and his areas of expertise include M&A, joint ventures, private equity and venture capital. He has been actively involved in several high profile cross-border transactions and is a leading member of Trilegal's corporate practice. Apart from representing a number of international clients on M&A in India, Mr. Gorthi has also advised Indian companies in connection with outbound M&A transactions in jurisdictions such as the UK, USA, South Africa, Argentina, Indonesia and Sri Lanka.

Mr. Gorthi has been named one of the leading lawyers in India for Mergers & Acquisitions, Private Equity and Venture Capital in India by the Guide to Asia Pacific’s Leading Lawyers 2010, 2011 and 2012; and by IFLR 1000, 2011 and 2012.

Independent Director
D R Mehta
+
Independent DirectorD R Mehta

Mr. D.R. Mehta joined the Indian Administrative Service in 1961 and held numerous important positions initially in the Government of Rajasthan and later in the Government of India. He has served as Chairman of SEBI, the Deputy Governor of the RBI, the Director General of Foreign Trade, Ministry of Commerce and Government of India. He was also the Controller of Capital Issues, Additional Secretary Banking in the Ministry of Finance in Government of India.  

Mr. Mehta is the founder and chief patron of Bhagwan Mahaveer Viklang Sahayata Samiti (BMVSS) Jaipur, the world's largest organization for the rehabilitation of the handicapped. He was conferred with the Padma Bhushan in 2008 and the Rajiv Gandhi National Sadbhavana Award in 2012. Mr. Mehta holds a Bachelors Degree in Arts and an LLB degree from the Rajasthan University. He also holds Management Degrees from Royal Institute of Public Administration, London and Alfred Sloan School of Management, MIT, Boston, US.

Independent Director
Dipankar Bhattacharjee
+
Independent DirectorDipankar Bhattacharjee

Mr. Dipankar Bhattacharjee has over 30 years of global experience leading Generics, Specialty and OTC Pharma, Medical Devices, and FMCG businesses, across key markets such as North America, Europe, APAC and MEA. This includes senior leadership positions such as President & CEO - Global Generics Medicines at Teva Pharmaceutical Industries, and senior leadership roles at Bausch & Lomb, Bank of America and Nestle.

With strong orientation towards stakeholders including investors, customers and patients, and deep understanding of payers and regulators, he has consistently delivered short term and long term results across multiple geographies and business environments. He has led high performing teams to develop and execute business strategies across all stages of business cycles, driving growth and value through commercial innovation and focussed R&D investments. He also has significant experience in Executive Management and Board interactions in shaping corporate strategy for various organisations.

Mr. Bhattacharjee holds a Master’s degree in Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Mumbai, and a Bachelor’s degree in Economics from St. Stephen’s College, University of Delhi.

Founder Emeritus

Late Mr. Gracias Saldanha

"Glenmark has been built on the pillars of Integrity, Knowledge, Trust & Respect"